Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
News|Articles|December 2, 2001
- Pharmaceutical Technology-12-02-2001
- Volume 25
- Issue 12
Outsourcing Outlook
Author(s)Jim Miller
Capacity is a pivotal commodity in the contract manufacturing business. If you have enough of the right kind of capacity, it's like platinum; conversely, too much of the wrong kind of capacity is like tin.
Advertisement
Articles in this issue
almost 25 years ago
Bioterrorism Threat Shines Spotlight on Drug Manufacturingalmost 25 years ago
E-Sourcing: Internet Facilitates Flexible Collaborationalmost 25 years ago
International Employment Survey 2001almost 25 years ago
A Comprehensive Approach to Pharmaceutical Engineering TrainingAdvertisement
Related to this article
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
Shilpa Pharma Lifesciences Limited will launch a new small-molecule CDMO at CPHI Milan in October.
This article explains the 4 shifts enabling faster, lower-risk, commercially successful biologics technology transfer.
Lilly is set to acquire Merida Biosciences for up to $2.875B, gaining a precision autoantibody-degrading platform led by phase 1 candidate MER511.
Advertisement
Advertisement